Glyscend Therapeutics

Glyscend Therapeutics is a venture-backed biopharmaceutical company dedicated to developing novel orally administered compounds that act on targets within the gastrointestinal tract to treat various metabolic diseases, including T2D. Glyscend's polymer technology platform stems from research at Johns Hopkins University, where scientists are evaluating mechanisms that significantly improve glucose and metabolic regulation following certain types of bariatric surgery.